Updated Jul 16, 2026
Eltoukhy Helmy has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $30.47M.

Helmy Eltoukhy is the Co-Chief Executive Officer and a Director at Guardant Health, Inc., a company specializing in liquid biopsy tests for cancer. He has played a significant role in advancing the company's innovative cancer diagnostic technologies.
| Role | Co-Chief Executive Officer, Director |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 17.1K | $170.77 | $2.92M |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 9.7K | $0.00 | |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 24.0K | $0.00 | |
| 2026-07-02 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 1.4K | $150.03 | $214K |
| 2026-07-02 | GH | Guardant Health, Inc. | M — Option exercise | 2.8K | $0.00 | |
| 2026-06-08 | GH | Guardant Health, Inc. | S — Open-market sale | 100 | $132.55 | $13K |
| 2026-06-08 | GH | Guardant Health, Inc. | S — Open-market sale | 900 | $131.78 | $119K |
| 2026-06-08 | GH | Guardant Health, Inc. | S — Open-market sale | 554 | $130.21 | $72K |
| 2026-06-08 | GH | Guardant Health, Inc. | S — Open-market sale | 13.8K | $128.25 | $1.77M |
| 2026-06-08 | GH | Guardant Health, Inc. | S — Open-market sale | 1.1K | $127.02 | $140K |
| 2026-06-08 | GH | Guardant Health, Inc. | S — Open-market sale | 33.8K | $126.33 | $4.28M |
| 2026-06-08 | GH | Guardant Health, Inc. | S — Open-market sale | 49.7K | $125.57 | $6.24M |
| 2026-04-02 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 17.1K | $91.15 | $1.56M |
| 2026-04-02 | GH | Guardant Health, Inc. | M — Option exercise | 9.7K | $0.00 | |
| 2026-04-02 | GH | Guardant Health, Inc. | M — Option exercise | 24.0K | $0.00 | |
| 2026-04-02 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 1.4K | $92.37 | $132K |
| 2026-04-02 | GH | Guardant Health, Inc. | M — Option exercise | 2.8K | $0.00 | |
| 2026-03-18 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 13.7K | $85.49 | $1.17M |
| 2026-03-18 | GH | Guardant Health, Inc. | M — Option exercise | 27.0K | $0.00 | |
| 2026-03-18 | GH | Guardant Health, Inc. | F — Tax withholding / forfeiture | 19.4K | $102.14 | $1.98M |
Helmy Eltoukhy is the Co-Chief Executive Officer and a Director at Guardant Health, Inc., a company specializing in liquid biopsy tests for cancer. He has played a significant role in advancing the company's innovative cancer diagnostic technologies.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 9 open-market sales ($30.47M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Eltoukhy Helmy profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.